Omnicell Inc. Stock
Omnicell Inc. Stock
There is an upward development for Omnicell Inc. compared to yesterday, with an increase of €0.60 (1.960%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Omnicell Inc..
With a target price of 38 € there is a positive potential of 21.79% for Omnicell Inc. compared to the current price of 31.2 €.
Pros and Cons of Omnicell Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omnicell Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omnicell Inc. | 1.960% | -3.106% | 6.122% | 14.706% | -19.588% | -44.286% | -72.389% |
| Healthequity Inc. | 0.000% | -8.966% | -6.383% | -11.409% | -15.385% | 29.412% | 8.875% |
| Bruker Corp. | 1.320% | -9.831% | 0.597% | -8.842% | -23.547% | - | - |
| Myriad Genetics | -0.250% | -5.724% | 2.934% | -36.457% | -23.868% | -79.518% | -83.195% |
Comments
Omnicell (OMCL) had its price target raised by Wells Fargo & Company from $52.00 to $55.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $70.00 price target on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for OMCL provided by MarketBeat
News
Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs
Corey J Manley, EVP & Chief Legal/Admin Officer at Omnicell (NASDAQ:OMCL), executed an open-market sale of 6,106 shares for $243,629.40 on Dec. 3, 2025, as reported in the SEC Form 4 filing.
Why Omnicell Stock Crushed the Market Today
Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares